Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,857 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.
de Botton S, Cluzeau T, Vigil C, Cook RJ, Rousselot P, Rizzieri DA, Liesveld JL, Fenaux P, Braun T, Banos A, Jurcic JG, Sekeres MA, Savona MR, Roboz GJ, Bixby D, Madigan K, Volkert A, Stephens K, Kang-Fortner Q, Baker K, Paul S, McKeown M, Carulli J, Eaton M, Hodgson G, Fiore C, Kelly MJ, Roth DA, Stein EM. de Botton S, et al. Among authors: baker k. Blood Adv. 2023 May 9;7(9):1858-1870. doi: 10.1182/bloodadvances.2022008806. Blood Adv. 2023. PMID: 36477975 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 36163766
[No title available]
[No authors listed] [No authors listed] PMID: 36163942
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.
Stein EM, de Botton S, Cluzeau T, Pigneux A, Liesveld JL, Cook RJ, Rousselot P, Rizzieri DA, Braun T, Roboz GJ, Lebon D, Heiblig M, Baker K, Volkert A, Paul S, Rajagopal N, Roth DA, Kelly M, Peterlin P. Stein EM, et al. Among authors: baker k. Leuk Lymphoma. 2023 Dec;64(12):1992-2001. doi: 10.1080/10428194.2023.2243356. Epub 2023 Aug 12. Leuk Lymphoma. 2023. PMID: 37571998 Free article.
Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-Versus-Host Disease Survivorship After Hematopoietic Cell Transplantation: Part IV. Patient Important Outcomes.
Rotz SJ, Wiener L, Baker KS, Choi SW, Phelan R, Cuvelier GDE, Duncan C, Williams KM, Qayed M. Rotz SJ, et al. Among authors: baker ks. Transplant Cell Ther. 2024 Dec 27:S2666-6367(24)00838-8. doi: 10.1016/j.jtct.2024.12.019. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39733839
2,857 results